3 Comments

Thank you! I appreciate your feedback!

Expand full comment

Great newsletter! I really appreciate all of your research.

You mentioned Evusheld. I'm immune compromised due to arthritis drugs and asked my primary care doctor (Stanford member) about it and got a response from an NP in her office saying it was only for people who could not get the vaccine. I don't believe that's true and am asking again. Maybe I should be asking my Rheumatologist instead. My sense is that many of the physicians are as confused as the patients about who's supposed to receive it. (I'm fully vaccinated with 3 + 2 boosters, but everyone is getting Covid.)

Thank you again - you are performing a very valuable service to all of us.

Best regards,

Mary Pope-Handy

Los Gatos CA

Expand full comment

Hi Mary,

Reading the latest FDA Evusheld recommendations, it seems that you would qualify if you are on an immunosuppressive drug. I would talk to your doctor about the FDA recommendations.

By the way, they are giving Evusheld at the Stanford Cancer Center.

Evusheld FAQs from the FDA: https://www.fda.gov/media/154703/download

"Q. What are some medical conditions or treatments that may lead to an inadequate immune response to the COVID-19 vaccination?

A: Medical conditions or treatments that may result in moderate to severe immunocompromise and an inadequate immune response to COVID-19 vaccination include but are not limited to:

 Active treatment for solid tumor and hematologic malignancies

 Receipt of solid-organ transplant and taking immunosuppressive therapy

 Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)

 Moderate or severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich

syndrome)

 Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm3

, history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of

symptomatic HIV)

 Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day

when administered for ≥2 weeks), alkylating agents, antimetabolites, transplant-related

immunosuppressive drugs, cancer chemotherapeutic agents classified as severely

immunosuppressive, tumor-necrosis (TNF) blockers, and other biologic agents that are

immunosuppressive or immunomodulatory (e.g., B-cell depleting agents)"

Expand full comment